Mario Gaudino1, Irbaz Hameed1,2, Michael E Farkouh3, Mohamed Rahouma1, Ajita Naik1, N Bryce Robinson1, Yongle Ruan1, Michelle Demetres4, Giuseppe Biondi-Zoccai5,6, Dominick J Angiolillo7, Emilia Bagiella8, Mary E Charlson9, Umberto Benedetto10, Marc Ruel11, David P Taggart12, Leonard N Girardi1, Deepak L Bhatt13, Stephen E Fremes14. 1. Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, New York. 2. Section of Cardiothoracic Surgery, Yale School of Medicine, New Haven, Connecticut. 3. Peter Munk Cardiac Centre, University of Toronto, Toronto, Ontario, Canada. 4. Samuel J. Wood Library and C. V. Starr Biomedical Information Center, Weill Cornell Medicine, New York, New York. 5. Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy. 6. Mediterranea Cardiocentro, Napoli, Italy. 7. Division of Cardiology, Department of Medicine, University of Florida College of Medicine-Jacksonville, Jacksonville. 8. Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York. 9. Division of General Internal Medicine, Weill Cornell Medical College, New York, New York. 10. Bristol Heart Institute, University of Bristol, Bristol, United Kingdom. 11. University of Ottawa Heart Institute, Ottawa, Ontario, Canada. 12. Nuffield Department of Surgical Sciences, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom. 13. Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, Massachusetts. 14. Schulich Heart Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
Abstract
Importance: Mortality is a common outcome in trials comparing percutaneous coronary intervention (PCI) with coronary artery bypass grafting (CABG). Controversy exists regarding whether all-cause mortality or cardiac mortality is preferred as a study end point, because noncardiac mortality should be unrelated to the treatment. Objective: To evaluate the difference in all-cause and cause-specific mortality in randomized clinical trials (RCTs) comparing PCI with CABG for the treatment of patients with coronary artery disease. Data Sources: MEDLINE (1946 to the present), Embase (1974 to the present), and the Cochrane Library (1992 to the present) databases were searched on November 24, 2019. Reference lists of included articles were also searched, and additional studies were included if appropriate. Study Selection: Articles were considered for inclusion if they were in English, were RCTs comparing PCI with drug-eluting or bare-metal stents and CABG for the treatment of coronary artery disease, and reported mortality and/or cause-specific mortality. Trials of PCI involving angioplasty without stenting were excluded. For each included trial, the publication with the longest follow-up duration for each outcome was selected. Data Extraction and Synthesis: For data extraction, all studies were reviewed by 2 independent investigators, and disagreements were resolved by a third investigator in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses guideline. Data were pooled using fixed- and random-effects models. Main Outcomes and Measures: The primary outcomes were all-cause and cause-specific (cardiac vs noncardiac) mortality. Subgroup analyses were performed for PCI trials using drug-eluting vs bare-metal stents and for trials involving patients with left main disease. Results: Twenty-three unique trials were included involving 13 620 unique patients (6829 undergoing PCI and 6791 undergoing CABG; men, 39.9%-99.0% of study populations; mean age range, 60.0-71.0 years). The weighted mean (SD) follow-up was 5.3 (3.6) years. Compared with CABG, PCI was associated with a higher rate of all-cause (incidence rate ratio, 1.17; 95% CI, 1.05-1.29) and cardiac (incidence rate ratio, 1.24; 95% CI, 1.05-1.45) mortality but also noncardiac mortality (incidence rate ratio, 1.19; 95% CI, 1.00-1.41). Conclusions and Relevance: Percutaneous coronary intervention was associated with higher all-cause, cardiac, and noncardiac mortality compared with CABG at 5 years. The significantly higher noncardiac mortality associated with PCI suggests that even noncardiac deaths after PCI may be procedure related and supports the use of all-cause mortality as the end point for myocardial revascularization trials.
Importance: Mortality is a common outcome in trials comparing percutaneous coronary intervention (PCI) with coronary artery bypass grafting (CABG). Controversy exists regarding whether all-cause mortality or cardiac mortality is preferred as a study end point, because noncardiac mortality should be unrelated to the treatment. Objective: To evaluate the difference in all-cause and cause-specific mortality in randomized clinical trials (RCTs) comparing PCI with CABG for the treatment of patients with coronary artery disease. Data Sources: MEDLINE (1946 to the present), Embase (1974 to the present), and the Cochrane Library (1992 to the present) databases were searched on November 24, 2019. Reference lists of included articles were also searched, and additional studies were included if appropriate. Study Selection: Articles were considered for inclusion if they were in English, were RCTs comparing PCI with drug-eluting or bare-metal stents and CABG for the treatment of coronary artery disease, and reported mortality and/or cause-specific mortality. Trials of PCI involving angioplasty without stenting were excluded. For each included trial, the publication with the longest follow-up duration for each outcome was selected. Data Extraction and Synthesis: For data extraction, all studies were reviewed by 2 independent investigators, and disagreements were resolved by a third investigator in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses guideline. Data were pooled using fixed- and random-effects models. Main Outcomes and Measures: The primary outcomes were all-cause and cause-specific (cardiac vs noncardiac) mortality. Subgroup analyses were performed for PCI trials using drug-eluting vs bare-metal stents and for trials involving patients with left main disease. Results: Twenty-three unique trials were included involving 13 620 unique patients (6829 undergoing PCI and 6791 undergoing CABG; men, 39.9%-99.0% of study populations; mean age range, 60.0-71.0 years). The weighted mean (SD) follow-up was 5.3 (3.6) years. Compared with CABG, PCI was associated with a higher rate of all-cause (incidence rate ratio, 1.17; 95% CI, 1.05-1.29) and cardiac (incidence rate ratio, 1.24; 95% CI, 1.05-1.45) mortality but also noncardiac mortality (incidence rate ratio, 1.19; 95% CI, 1.00-1.41). Conclusions and Relevance: Percutaneous coronary intervention was associated with higher all-cause, cardiac, and noncardiac mortality compared with CABG at 5 years. The significantly higher noncardiac mortality associated with PCI suggests that even noncardiac deaths after PCI may be procedure related and supports the use of all-cause mortality as the end point for myocardial revascularization trials.
Authors: Friedrich W Mohr; Marie-Claude Morice; A Pieter Kappetein; Ted E Feldman; Elisabeth Ståhle; Antonio Colombo; Michael J Mack; David R Holmes; Marie-angèle Morel; Nic Van Dyck; Vicki M Houle; Keith D Dawkins; Patrick W Serruys Journal: Lancet Date: 2013-02-23 Impact factor: 79.321
Authors: Timo Mäkikallio; Niels R Holm; Mitchell Lindsay; Mark S Spence; Andrejs Erglis; Ian B A Menown; Thor Trovik; Markku Eskola; Hannu Romppanen; Thomas Kellerth; Jan Ravkilde; Lisette O Jensen; Gintaras Kalinauskas; Rikard B A Linder; Markku Pentikainen; Anders Hervold; Adrian Banning; Azfar Zaman; Jamen Cotton; Erlend Eriksen; Sulev Margus; Henrik T Sørensen; Per H Nielsen; Matti Niemelä; Kari Kervinen; Jens F Lassen; Michael Maeng; Keith Oldroyd; Geoff Berg; Simon J Walsh; Colm G Hanratty; Indulis Kumsars; Peteris Stradins; Terje K Steigen; Ole Fröbert; Alastair N J Graham; Petter C Endresen; Matthias Corbascio; Olli Kajander; Uday Trivedi; Juha Hartikainen; Vesa Anttila; David Hildick-Smith; Leif Thuesen; Evald H Christiansen Journal: Lancet Date: 2016-10-31 Impact factor: 79.321
Authors: Torsten Doenst; Axel Haverich; Patrick Serruys; Robert O Bonow; Pieter Kappetein; Volkmar Falk; Eric Velazquez; Anno Diegeler; Holger Sigusch Journal: J Am Coll Cardiol Date: 2019-03-05 Impact factor: 24.094
Authors: Laura Mauri; David Cox; James Hermiller; Joseph Massaro; Joyce Wahr; Sew Wah Tay; Michael Jonas; Jeffrey J Popma; Jim Pavliska; Dennis Wahr; Campbell Rogers Journal: J Am Coll Cardiol Date: 2007-09-24 Impact factor: 24.094
Authors: Michael E Farkouh; Michael Domanski; Lynn A Sleeper; Flora S Siami; George Dangas; Michael Mack; May Yang; David J Cohen; Yves Rosenberg; Scott D Solomon; Akshay S Desai; Bernard J Gersh; Elizabeth A Magnuson; Alexandra Lansky; Robin Boineau; Jesse Weinberger; Krishnan Ramanathan; J Eduardo Sousa; Jamie Rankin; Balram Bhargava; John Buse; Whady Hueb; Craig R Smith; Victoria Muratov; Sameer Bansilal; Spencer King; Michel Bertrand; Valentin Fuster Journal: N Engl J Med Date: 2012-11-04 Impact factor: 91.245
Authors: Bhuvnesh Aggarwal; Stephen G Ellis; A Michael Lincoff; Samir R Kapadia; Joseph Cacchione; Russell E Raymond; Leslie Cho; Christopher Bajzer; Ravi Nair; Irving Franco; Conrad Simpfendorfer; E Murat Tuzcu; Patrick L Whitlow; Mehdi H Shishehbor Journal: J Am Coll Cardiol Date: 2013-05-09 Impact factor: 24.094
Authors: Ruth Masterson Creber; Arnaldo Dimagli; Cristiano Spadaccio; Annie Myers; Marco Moscarelli; Michelle Demetres; Matthew Little; Stephen Fremes; Mario Gaudino Journal: Eur Heart J Qual Care Clin Outcomes Date: 2022-05-05
Authors: Edward L Hannan; Yi-Feng Wu; Kimberly Cozzens; Jacqueline Tamis-Holland; Frederick S K Ling; Alice K Jacobs; Ferdinand J Venditti; Peter B Berger; Gary Walford; Spencer B King Iii Journal: J Geriatr Cardiol Date: 2021-03-28 Impact factor: 3.327
Authors: Piroze M Davierwala; Chao Gao; Daniel J F M Thuijs; Rutao Wang; Hironori Hara; Masafumi Ono; Thilo Noack; Scot Garg; Neil O'leary; Milan Milojevic; Arie Pieter Kappetein; Marie-Claude Morice; Michael J Mack; Robert-Jan van Geuns; David R Holmes; Mario Gaudino; David P Taggart; Yoshinobu Onuma; Friedrich Wilhelm Mohr; Patrick W Serruys Journal: Eur Heart J Date: 2022-03-31 Impact factor: 29.983
Authors: Rutao Wang; Patrick W Serruys; Chao Gao; Hironori Hara; Kuniaki Takahashi; Masafumi Ono; Hideyuki Kawashima; Neil O'leary; David R Holmes; Adam Witkowski; Nick Curzen; Francesco Burzotta; Stefan James; Robert-Jan van Geuns; Arie Pieter Kappetein; Marie-Angele Morel; Stuart J Head; Daniel J F M Thuijs; Piroze M Davierwala; Timothy O'Brien; Valentin Fuster; Scot Garg; Yoshinobu Onuma Journal: Eur Heart J Date: 2021-12-28 Impact factor: 29.983